The Indian Journal of Pediatrics

, Volume 75, Issue 6, pp 621–627 | Cite as

Probiotic use in the critically ILL

Symposium on Advances in Pediatric Intensive Care

Abstract

Probiotics are “live microbes which when administered in adequate amounts confer a health benefit to the host” (FAO/WHO joint group). Their potential role in bio-ecological modification of pathological internal milieu of the critically ill is under evaluation. Probiotics are available as single microbial strain (e.g., Bacillus clausii, Lactobacillus) or as a mix of multiple strains of Lactobacillus (acidophilus, sporogenes, lactis, reuteri RC-14, GG, and L. plantarum 299v), Bifidobacterium (bifidum, longum, infantis), Streptococcus (thermophillus, lactis, fecalis), Saccharomyces boulardii etc. Lactobacilli and Bifidobacteria are grampositive, anaerobic, lactic acid bacteria. These are normal inhabitant of human gut and colonize the colon better than others. Critical illness and its treatment create hostile environment in the gut and alters the micro flora favoring growth of pathogens. Therapy with probiotics is an effort to reduce or eliminate potential pathogens and toxins, to release nutrients, antioxidants, growth factors and coagulation factors, to stimulate gut motility and to modulate innate and adaptive immune defense mechanisms via the normalization of altered gut flora. Scientific evidence shows that use of probiotics is effective in prevention and therapy of antibiotic associated diarrhea. However, available probiotics strains in currently used doses do not provide much needed early benefits, and need long-term administration to have clinically beneficial effects (viz, a reduction in rate of infection, severe sepsis, ICU stay, ventilation days and mortality) in critically ill surgical and trauma patients. Possibly, available strains do not adhere to intestinal mucosa early, or may require higher dose than what is used. Gap exists in our knowledge regarding mechanisms of action of different probiotics, most effective strains-single or multiple, cost effectiveness, risk-benefit potential, optimum dose, frequency and duration of treatment etc. More information is needed on safety profile of probiotics in immunocompromised state of the critically ill in view of rare reports of fungemia and sepsis and a trend toward possible increase in nosocomial infection. At present, despite theoretical potential benefits, available evidence is not conclusive to recommend probiotics for routine use in the critically ill.

Key words

Probiotics Critically ill Intensive Care unit Children 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Lilly DM, Stillwell RH. Probiotics: growth promoting factors produced by micro-organisms. Science 1965; 147: 747–748.PubMedCrossRefGoogle Scholar
  2. 2.
    Joint FAO/WHO Working Group. Guidelines for the evaluation of probiotics in food. London, Ontario, Canada. 2002.Google Scholar
  3. 3.
    Guarner F, Malagelada JR. Gut Flora in health and disease. Lancet 2003; 361: 512–519.PubMedCrossRefGoogle Scholar
  4. 4.
    Noverr MC, Huffnagle GB. The ‘microflora hypothesis’ of allergic diseases. Clin Exp Allergy 2005; 35: 1511–1520.PubMedCrossRefGoogle Scholar
  5. 5.
    O’sullivan GC. Probiotics. Br J Surg 2001; 88: 161–162.PubMedCrossRefGoogle Scholar
  6. 6.
    Frankel WL, Zhang W, Singh A et al. Mediation of the trophic effects of short-chain fatty acids on the rat jejunum and colon. Gastroenterology 1994; 106: 375–380.PubMedGoogle Scholar
  7. 7.
    Roberfroid MB, Bornet F, Bouley C, Cummings JH. Colonic microflora: nutrition and health: summary and conclusions of an International Life Sciences Institute (Europe) workshop held in Barcelona, Spain. Nutr Rev 1995; 53: 127–130.PubMedCrossRefGoogle Scholar
  8. 8.
    Conly JM, Stein K, Worobetz L, Rutledge-Harding S. The contribution of vitamin K2 (metaquinones) produced by the intestinal microflora to human nutritional requirements for vitamin K. Am J Gastroenterol 1994; 89: 915–923.PubMedGoogle Scholar
  9. 9.
    Younes H, Coudray C, Bellanger J et al. Effects of two fermentable carbohydrates (inulin and resistant starch) and their combination on calcium and magnesium balance in rats. Br J Nutr 2001; 86: 479–485.PubMedCrossRefGoogle Scholar
  10. 10.
    Freestone PP, Haigh RD, Williams PH et al. Stimulation of bacterial growth by heat-stable, norepinephrine-induced autoinducers. FEMS Micobiol Lett 1991; 172: 53–60.CrossRefGoogle Scholar
  11. 11.
    Alverdy JC, Laughlin RS, Wu L. Influence of the critically ill state on host-pathogen interactions within the intestine: Gutderived sepsis redefined. Crit Care Med 2003; 31: 598–607.PubMedCrossRefGoogle Scholar
  12. 12.
    Wang X, Andersson R, Soltesz V et al. Gut origin sepsis, macrophage function, and oxygen extraction associated with acute pancreatitis in the rat. World J Surg 1996; 20: 299–307.PubMedCrossRefGoogle Scholar
  13. 13.
    Knight DJW, Ala’ Aldeen D, Bengmark S, Girling KJ. The effect of synbiotics on gastrointestinal flora in the critically ill. (abstract). Br J Anaesth 2004; 92: 307–308.Google Scholar
  14. 14.
    Kinney KS, Austin CE, Morton DS et al. Nor-epinephrine as a growth-stimulating factor in bacteria: Mechanistic studies. Life Sci 2000; 67: 3075–3085.PubMedCrossRefGoogle Scholar
  15. 15.
    Leveau P, Wang X Soltesz V, Ihse I, Andersson R. Alterations in intestinal permeability and micro flora in experimental acute pancreatitis. Int J Pancreat 1996; 20: 119–125.Google Scholar
  16. 16.
    Andersson R, Wang X, Ihse I, Leveau P. The influence of abdominal sepsis on acute pancreatitis in rats: a study on mortality, permeability, arterial blood pressure and intestinal blood flow. Pancreas 1995; 11: 365–373.PubMedCrossRefGoogle Scholar
  17. 17.
    MacFie J, O’Boyle C, Mitchell CJ, Buckley PM, Johnstone D, Sudworth P. Gut origin of sepsis: a prospective study investigating associations between bacterial translocation, gastric microflora, and septic morbidity. Gut 1999; 45: 223–228.PubMedCrossRefGoogle Scholar
  18. 18.
    Bengmark S. Bio-ecology control of the gastrointestinal tract: The role of flora and supplemented probiotics and synbiotics. Gastroenterol Clin North Am 2005; 34: 13–36, viii.CrossRefGoogle Scholar
  19. 19.
    Alberda C, Gramlich L, Meddings J et al. Effects of probiotics therapy in critically ill patients: a randomized, double-blind, placebo-controlled trial. Am J Clin Nutr 2007; 85: 816–823.PubMedGoogle Scholar
  20. 20.
    Meie R, Steuerwals M. Place of probiotics. Curr Opin Crit Care 2005; 11: 318–325.CrossRefGoogle Scholar
  21. 21.
    Gomes AMP, Malcata FK. Bifidobacterium spp. and Lactobacillus acidophilus: biological, biochemical, technological and therapeutic properties relevant for use as probiotics. Trends Food Sci Technol 1999; 10: 139–157.CrossRefGoogle Scholar
  22. 22.
    Srinivasan R, Meyer R, Padmnabhan R, Britto J. Clinical safety of Lactobacillus casei shirota as a probiotic in critical ill children. J Pediatr Gastroenterol Nutr 2006; 42: 171–173.PubMedCrossRefGoogle Scholar
  23. 23.
    Mohan R, Koebnick C, Schildt J et al. Effects of Bifidobacterium lactis Bb 12 supplementation on intestinal microbiota of preterm infants: a double-blind, placebo-controlled, randomized study. J Clin Microbial 2006; 44: 4025–4031.CrossRefGoogle Scholar
  24. 24.
    Klarin B, Johansson ML, Molin G, Larsson A, Jeppsson B. Adhesion of the probiotic bacterium Lactobacillus plantarum 299v onto the gut mucosa in critically ill patients: a randomized open trial. Crit Care 2005; 9: R285–293.PubMedCrossRefGoogle Scholar
  25. 25.
    Manzoni P, Mostert M, Leonessa ML et al. Oral supplementation with Lactobacillus casei subspecies rhamnosus prevents enteric clononization by Candida species in preterm neonates: a randomized study. Clin Infect Dis 2006; 42: 1735–1742.PubMedCrossRefGoogle Scholar
  26. 26.
    Jain PK, McNaught CE, Anderson AD, MacFie J, Mitchell CJ. Influence of synbiotic containing Lactobacillus acidophilus La5, Bifidobacterium lactis Bb12, Streptococcus thermophilus, Lactobacillus bulgaricus and oligofructose on gut barrier function and sepsis in critically ill patients: a randomized controlled trial. Clin Nutr 2004; 23: 467–475.PubMedCrossRefGoogle Scholar
  27. 27.
    Mangell P, Lennernas P, Wang M et al. Adhesive capability of Lactobacillus plantarum 299v is important for preventing bacterial translocation in endotoxemic rats. APMIS 2006; 114: 611–618.PubMedCrossRefGoogle Scholar
  28. 28.
    Dani C, Biadaioli R, Bertini G, Martelli E, Rubaltelli FF. Probiotics feeding in prevention of urinary tract infection, bacterial sepsis and necrotizing enterocolitis in preterm infants. A prospective double-blind study. Biol Neonate 2002; 82: 103–108.PubMedCrossRefGoogle Scholar
  29. 29.
    McNaught CE, Woodcock NP, Anderson AD, MacFie J. A prospective randomized trial of probiotics in critically ill patients. Clin Nutr 2005; 24: 211–219.PubMedCrossRefGoogle Scholar
  30. 30.
    Honeycutt TC, El Khashab M, Wardrop RM 3rd et al. Probiotic administration and the incidence of nosocomial infection in pediatric intensive care: A randomized placebocontrolled trial. Pediatr Crit Care Med 2007; 8: 452–458.PubMedGoogle Scholar
  31. 31.
    Watkinson PJ, Barber VS, Dark P, Young JD. The use of pre-pro-and synbiotics in adult intensive care unit patients: systematic review. Clin Nutr 2007; 26: 182–192.PubMedCrossRefGoogle Scholar
  32. 32.
    Kotzampassi K. Giamarellos-Bourboulis EJ, Voudouris A, Kazamias P, Eleftheriadis E. Benefits of a symbiotic formula (Synbiotic 2000Forte) in critically ill trauma patients: early results of a randomized controlled trial. World J Surg 2006; 30: 1848–1855.PubMedCrossRefGoogle Scholar
  33. 33.
    Falcao de Arruda IS, de Aguilar-Nascimento JE. Benefits of early enteral nutrition with glutamine and probiotics in brain injury patients. Clin Sci (Lond) 2004; 106: 287–292.CrossRefGoogle Scholar
  34. 34.
    Bin-Nun A, Bromiker R, Wilschanski M et al. Oral probiotics prevent necrotizing enterocolitis in very low birth weight neonates. J Pediatr 2005; 147: 192–196.PubMedCrossRefGoogle Scholar
  35. 35.
    Baranwal AK, Singhi SC, Jayashree M. A 5-year PICU experience of Disseminated Staphylococcal Disease, Part 1: Clinical and Microbial Profile. J Trop Pediatr 2007; 53: 245–51.PubMedCrossRefGoogle Scholar
  36. 36.
    Heyland DK, Dhaliwal R, Drover JW, Gramlich L, Dodek P; Canadian Critical Care Clinical Practice Guidelines Committee. Canadian clinical practice guidelines for nutrition support in mechanically ventilated, critically ill adult patients. J Parenter Enteral Nutr 2003; 27: 355–373.CrossRefGoogle Scholar
  37. 37.
    Nathens AB, Curtis JR, Beale RJ et al. Management of the critically ill patient with severe acute pancreatitis. Crit Care Med 2004; 32: 2524–2536.PubMedCrossRefGoogle Scholar
  38. 38.
    Beaugerie L, Petit JC. Microbial-gut interactions in health and disease: Antibiotic-associated diarrhoea. Best Pract Res Clin Gastroenterol 2004; 18: 337–352.PubMedCrossRefGoogle Scholar
  39. 39.
    D’souza Al, Rajkumar C, Cooke J, Bulpitt CJ. Probiotics in prevention of antibiotic-associated diarrhea: meta-analysis. BMJ 2002; 324: 1361.PubMedCrossRefGoogle Scholar
  40. 40.
    Szajewska H, Ruszczynski M, Radzikowski A. Probiotics in prevention of antibiotic-associated diarrhea in children: a meta-analysis of randomized controlled trials. J Pediatr 2006; 149: 367–372.PubMedCrossRefGoogle Scholar
  41. 41.
    Cremonini F, Di Caro S, Nista EC et al. Meta-analysis: the effect of probiotic administration on antibiotic-associated diarrhea. Aliment Pharmacol Ther 2002; 16: 1461–1467.PubMedCrossRefGoogle Scholar
  42. 42.
    Johnston BC, Supina AL, Vohra S. Probiotics for pediatric antibiotic-associated diarrhea: a meta-analysis of randomized placebo-controlled trials. CMAJ 2006; 175: 377–383.PubMedGoogle Scholar
  43. 43.
    Wiesen P, Van Gossum A, Preiser JC. Diarrhoea in the critically ill. Curr Opin Crit Care 2006; 12: 149–154.PubMedCrossRefGoogle Scholar
  44. 44.
    Hammerman C, Bin-Nun A, Kaplan M. Safety of probiotics: comparison of two popular strains. BMJ 2006; 333: 1006–1008.PubMedCrossRefGoogle Scholar
  45. 45.
    Sugawara G, Nagino M, Nishio H et al. Perioperative synbiotic treatment to prevent postoperative infectious complications in biliary cancer surgery: A randomized controlled trial. Ann Surg 2006; 244: 706–714.PubMedCrossRefGoogle Scholar
  46. 46.
    Lestin F, Persehy A, Rimek D. Fungemia after oral treatment with Saccharomyes boulardii in a patient with multiple Comorbidities. Dtsch Med Wochensehr 2003; 128: 2531–2533.CrossRefGoogle Scholar
  47. 47.
    Munoz P, Bouza E, Cuenca-Estrella M et al. Saccharomyces cerevisiae fungemia: an emerging infectious disease. Clin Infect Dis 2005; 40: 1625–1634.PubMedCrossRefGoogle Scholar
  48. 48.
    Hennequin C, Kauffman Lacroix C, Jobert A et al. Possible role of catheters in Saccharomyces boullardii fungemia. Eur J Clin Micribiol Infect Dis 2000; 19: 16–20.CrossRefGoogle Scholar
  49. 49.
    ESPGHAN Committee on Nutrition. Probiotic bacteria in dietetic products for infants: a commentary by the ESPGHAN committee on nutrition. J Pediatr Gastroenterol Nutr 2004; 38: 365–374.CrossRefGoogle Scholar

Copyright information

© Dr. K C Chaudhuri Foundation 2008

Authors and Affiliations

  1. 1.Department of Pediatrics, Advanced Pediatrics CenterPostgraduate Institute of Medical Education and ResearchChandigarhIndia

Personalised recommendations